RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
284.00
-0.50 (-0.18%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close284.50
Open286.70
Bid281.90 x 400800
Ask284.00 x 100
Day's Range277.00 - 286.70
52 Week Range157.00 - 529.90
Volume103,501
Avg. Volume499,554
Market Cap724.501M
Beta0.16
PE Ratio (TTM)N/A
EPS (TTM)-0.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
  • GlobeNewswireyesterday

    RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference

    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference, on Tuesday, Oct. 2, 2018, at 10:30 a.m. ET, at the Sofitel Hotel in New York City.

  • GlobeNewswire9 days ago

    RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D

    The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome, one of the most common gastrointestinal disorders In light ...

  • GlobeNewswire15 days ago

    RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma

    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that the ongoing single-arm Phase IIa study with orally-administered YELIVA® (opaganib, ABC294640)1 for the treatment of advanced cholangiocarcinoma (bile duct cancer) has achieved its pre-specified efficacy goal for the first stage of the two-stage study design, and as a result, the study will continue to its second stage, enrolling the full cohort of 39 evaluable patients. The primary efficacy endpoint of the study is defined as either partial or complete response, or stable disease at four months treatment with YELIVA®.

  • GlobeNewswire17 days ago

    RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection

    Top-line results from the randomized, double-blind confirmatory Phase III study with TALICIA ® are expected before year’ s end The ERADICATE Hp2 study enrolled 455 patients with confirmed H. pylori infection ...

  • GlobeNewswire22 days ago

    RedHill Biopharma Reports Second Quarter 2018 Financial Results and Provides Update on Operations

    Top-line results from confirmatory Phase III study with TALICIA ® for H. pylori infection on track to be announced in the fourth quarter of 2018 Positive top-line results from Phase III study with RHB-104 ...

  • GlobeNewswire28 days ago

    RedHill Biopharma to Host Second Quarter 2018 Financial Results Conference Call on August 30, 2018

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it will report its second quarter 2018 financial results on Thursday, August 30, 2018. The Company will host a conference call on Thursday, August 30, 2018 at 8:30 a.m. EDT to review the financial results and business highlights. The conference call will be broadcast live and will be available for replay on the Company's website, http://ir.redhillbio.com/events, for 30 days.

  • GlobeNewswirelast month

    RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a new formulation patent covering RHB-106, which is expected to be valid until at least 2033. RHB-106 is an encapsulated bowel cleanser licensed to Salix Pharmaceuticals (“Salix”), a wholly-owned subsidiary of Bausch Health Companies Inc. (NYSE: BHC and TSX: BHC).

  • GlobeNewswirelast month

    RedHill Biopharma Announces Closing of $25 Million Underwritten Offering

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the closing of its previously announced underwritten offering of 4,166,667 American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, at an offering price of $6.00 per ADS, for gross proceeds of approximately $25 million, before commissions and other offering expenses. The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund clinical development programs, including preparations for a second Phase III study with RHB-104 for Crohn’s disease, initiation of a pivotal Phase III study with RHB-204 for NTM, for commercial operations including TALICIA® (H. pylori) launch preparations, acquisitions, and general corporate purposes.

  • GlobeNewswirelast month

    RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 13, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a new formulation patent, expected to be valid until at least 2029, that further expands the Company’s intellectual property portfolio covering RHB-104 for Crohn’s disease and RHB-204 for pulmonary nontuberculous mycobacteria (NTM) infections. Danielle Abramson, Ph.D., RedHill’s Vice President, Intellectual Property & Research, said: “RedHill has a robust patent portfolio covering the proprietary formulation of RHB-104 and its use in treating Crohn’s disease, including several issued U.S. patents.

  • GlobeNewswirelast month

    RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the pricing of an underwritten offering of 4,166,667 American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, at an offering price of $6.00 per ADS, for gross proceeds of approximately $25 million, before commissions and other offering expenses. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American:LTS), is acting as the sole book-running manager for the offering. The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund clinical development programs, including preparations for a second Phase III study with RHB-104 for Crohn’s disease, initiation of a pivotal Phase III study with RHB-204 for NTM, for commercial operations including TALICIA® (H. pylori) launch preparations, acquisitions, and general corporate purposes.

  • GlobeNewswire2 months ago

    RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today elaborated on the previously announced positive top-line results from the first Phase III study with orally-administered RHB-104 for Crohn’s disease (the MAP US study). “Based on the feedback from our shareholders, stakeholders and other market participants, we believe certain aspects of our MAP US Phase III study top-line results may not have been sufficiently clear, particularly in relation to the secondary endpoint of standalone week 52 remission. The Company reiterates that its MAP US first Phase III study with RHB-104 successfully met its primary endpoint, as well as key secondary endpoints, demonstrating consistent benefit to Crohn’s disease patients treated with RHB-104.

  • Why Redhill Biopharma Ltd. Stock Is Soaring Today
    Motley Fool2 months ago

    Why Redhill Biopharma Ltd. Stock Is Soaring Today

    Redhill's late-stage Crohn's disease drug hits the mark in a late-stage trial.

  • Benzinga2 months ago

    RedHill Earns Long-Awaited Boost On Positive Crohn's Data

    REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) achieved positive top-line results in its Phase 3 study of RHB-104 in Crohn’s disease, according to a Monday press release . What Happened The drug met both primary ...

  • Reuters2 months ago

    RedHill BioPharma has positive results from Crohn's disease trial

    Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104. The study met its primary endpoint and key secondary endpoints, demonstrating the drug's superiority over a placebo in achieving remission of the gastrointestinal disease at week 26, the company said in a statement. "The proportion of patients meeting the primary endpoint was significantly greater in the RHB-104 group compared to placebo," RedHill said.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today announced positive top-line safety and efficacy results from the first Phase III study with RHB-104 for Crohn’s disease (the MAP US study). The study successfully met its primary endpoint and key secondary endpoints.

  • GlobeNewswire2 months ago

    RedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi®

    Mytesi ® is an FDA-approved anti-diarrheal prescription drug indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on anti-retroviral therapy Mytesi ® is the fourth product ...

  • GlobeNewswire2 months ago

    RedHill Biopharma Enrolls 400th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection

    TEL-AVIV, Israel and RALEIGH, N.C., July 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that it has enrolled 400 of the planned total of 444 patients in the ongoing confirmatory Phase III study investigating TALICIA® (RHB-105)1 for H. pylori infection (ERADICATE Hp2). “RedHill is on track to complete enrollment of the ERADICATE Hp2 study in the coming weeks, and we expect to announce top-line results in the fourth quarter of this year,” said Dror Ben-Asher, RedHill’s Chief Executive Officer.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Uplisting to Nasdaq Global Market

    TEL-AVIV, Israel and RALEIGH, N.C., July 23, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that Nasdaq Stock Market LLC has approved the uplisting of the Company’s American Depositary Shares (“ADSs”) on the Nasdaq Global Market. The ADSs were previously traded on the Nasdaq Capital Market.

  • RedHill Gets Two New Patents for Crohn's Disease Candidate
    Zacks3 months ago

    RedHill Gets Two New Patents for Crohn's Disease Candidate

    RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.

  • RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%
    Zacks3 months ago

    RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%

    RedHill Biopharma (RDHL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • GlobeNewswire3 months ago

    RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., July 02, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal (GI) diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) and an Intention to Grant from the European Patent Office (EPO) for two new patents covering RHB-104, expected to be valid until at least February 5, 2029, once granted. The development of RHB-104 for Crohn’s disease is based on the hypothesis that Crohn’s disease is caused by Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients.

  • GlobeNewswire3 months ago

    RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®

    RedHill has been granted the exclusive right to co-promote Mytesi ® in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by ...

  • RedHill Biopharma (RDHL): Moving Average Crossover Alert
    Zacks3 months ago

    RedHill Biopharma (RDHL): Moving Average Crossover Alert

    RedHill Biopharma Ltd. (RDHL) is looking like an interesting pick from a technical perspective

  • RedHill Biopharma (RDHL) Shares March Higher, Can It Continue?
    Zacks3 months ago

    RedHill Biopharma (RDHL) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in RedHill Biopharma Ltd. (RDHL)